CWM
IMUC

Catamount Wealth Management’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Catamount Wealth Management’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-25
Closed – – 189
2016
Q3 		$0 Hold
25
– – ﹤0.01% 177
2016
Q2 		$0 Hold
25
– – ﹤0.01% 149
2016
Q1 		$0 Hold
25
– – ﹤0.01% 147
2015
Q4 		$0 Hold
25
– – ﹤0.01% 153
2015
Q3 		$0 Hold
25
– – ﹤0.01% 223
2015
Q2 		$0 Hold
25
– – ﹤0.01% 216
2015
Q1 		$0 Hold
25
– – ﹤0.01% 187
2014
Q4 		$1K Buy
+25
New +$720 ﹤0.01% 128

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Catamount Wealth Management's IMUC Position: Q4 2016 in Review

Catamount Wealth Management sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2016, closing a stake of 25 shares.

Catamount Wealth Management first reported a position in IMUC in Q4 2014 and held it in 8 quarters. The position peaked at $1K in Q4 2014. 16 funds tracked by Wall St. Rank hold IMUC as of Q4 2016.

  • Catamount Wealth Management reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2016 after selling out during the quarter.
  • Catamount Wealth Management sold 25 ImmunoCellular Therapeutics, Ltd. shares in Q4 2016.
  • Catamount Wealth Management first reported a position in ImmunoCellular Therapeutics, Ltd. in Q4 2014 and held it in 8 quarters.
  • Catamount Wealth Management's ImmunoCellular Therapeutics, Ltd. position peaked at $1K in Q4 2014.
  • 16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2016.

Based on Catamount Wealth Management's 13F filing for Q4 2016, filed 14 Feb 2017.